Pharma Update

Young portfolio: 20 NMEs launched since 2015 driving growth Keeping launch momentum with two NMEs approved in 2023 Roche TECENTRIQ atezolizumab VENCLEXTA LUXTURNA voretigene reparvoveczy HEMLIBRA emicizumab-kawh ALECENSA alectinib OCREVUS ocrelinumab COTELLIC xofluza POLIVY ENSPRYNG PHESGO ROZLYTREK Evrysdi. VABYSMO GAVRETO SUSVIMO Lunsumio RONAPREVE mosunetuzumab CHFM 12,000 10,000 8,000 6,000 22% Elevidys* 4,000 COLUMVI 2,000 33% 41% % of Pharma Sales** 50% 2015 | 2016 | 2017 | 2018 | 2019 | 2020 2021 2022 2023 0 HY 2020 Cotellic Luxturna HY 2021 Alecensa Xofluza HY 2022 HY 2023 Phesgo Vabysmo | Evrysdi Lunsumio Tecentriq Polivy Gavreto Ocrevus Rozlytrek Hemlibra Enspryng Ronapreve Susvimo Columvi Young portfolio defined as all launches since end of 2015; * Elevidys: Accelerated US approval by partner company Sarepta; ** Venclexta sales booked by AbbVie and therefore not included 15

View entire presentation